Neurocrine Biosciences reported $375.3M in EBITDA for its fiscal quarter ending in September of 2026.





Ebitda Change Date
AbbVie USD 6.91B 3.22B Jun/2026
Acadia Pharmaceuticals USD 40.99M 42.62M Jun/2026
Agios Pharmaceuticals USD -109.2M 540K Jun/2026
ALKERMES USD 120.06M 19.15M Sep/2026
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
Amgen USD 5.8B 1.25B Sep/2026
Biogen USD 450.8M 198.9M Jun/2026
BioMarin Pharmaceutical USD 54.32M 167.99M Sep/2026
Cytokinetics USD -160.3M 9.02M Jun/2026
Exelixis USD 275.36M 19.96M Sep/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
Halozyme Therapeutics USD 336.16M 7.34M Sep/2026
Incyte USD 778.57M 410.6M Jun/2026
Ionis Pharmaceuticals USD -95.22M 9.99M Sep/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Neurocrine Biosciences USD 375.3M 185.4M Sep/2026
Pfizer USD 6.36B 350M Sep/2026
Prothena USD -18.49M 44.46M Jun/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Repligen USD 43.84M 70K Sep/2026
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Sarepta Therapeutics USD -3.14M 33.31M Sep/2026
Teva Pharmaceutical Industries USD 1.5B 1.02B Sep/2026
Ultragenyx Pharmaceutical USD -61M 94M Jun/2026
Vertex Pharmaceuticals USD 888.6M 436.6M Sep/2026